Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Up 13.6% in January

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 595,300 shares, an increase of 13.6% from the December 31st total of 523,900 shares. Approximately 7.5% of the shares of the company are short sold. Based on an average daily trading volume, of 260,300 shares, the short-interest ratio is presently 2.3 days.

Citius Pharmaceuticals Stock Performance

Shares of Citius Pharmaceuticals stock traded down $0.02 on Monday, reaching $2.67. 29,323 shares of the company were exchanged, compared to its average volume of 110,853. The company’s 50-day moving average is $3.33 and its two-hundred day moving average is $9.91. The firm has a market cap of $22.94 million, a price-to-earnings ratio of -0.45 and a beta of 1.30. Citius Pharmaceuticals has a 1-year low of $2.44 and a 1-year high of $26.75.

Institutional Trading of Citius Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 DIFC Ltd acquired a new stake in Citius Pharmaceuticals in the 2nd quarter valued at approximately $29,000. XTX Topco Ltd acquired a new stake in Citius Pharmaceuticals in the 3rd quarter valued at approximately $47,000. Miller Investment Management LP boosted its stake in Citius Pharmaceuticals by 99.3% during the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after purchasing an additional 49,640 shares in the last quarter. Virtu Financial LLC bought a new position in Citius Pharmaceuticals during the 3rd quarter valued at $50,000. Finally, Cubist Systematic Strategies LLC bought a new position in Citius Pharmaceuticals during the 2nd quarter valued at $69,000. 16.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CTXR has been the topic of a number of research analyst reports. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Citius Pharmaceuticals in a report on Tuesday, January 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.